Trial Outcomes & Findings for Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients (NCT NCT01118221)

NCT ID: NCT01118221

Last Updated: 2015-03-04

Results Overview

Change in 6 Minute Walk Distance from Baseline to 3 Months

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

25 participants

Primary outcome timeframe

The 6-MWD will be measured at 0 and 3 months.

Results posted on

2015-03-04

Participant Flow

Participant milestones

Participant milestones
Measure
Pulmonary Rehabilitation
enroll in pulmonary rehabilitation program pulmonary rehabilitation: structured exercise program
Control
no structured exercise
Overall Study
STARTED
14
11
Overall Study
COMPLETED
11
10
Overall Study
NOT COMPLETED
3
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Pulmonary Rehabilitation
n=14 Participants
enroll in pulmonary rehabilitation program pulmonary rehabilitation: structured exercise program
Control
n=11 Participants
no structured exercise
Total
n=25 Participants
Total of all reporting groups
Age, Continuous
71 years
STANDARD_DEVIATION 6 • n=5 Participants
66 years
STANDARD_DEVIATION 7 • n=7 Participants
69 years
STANDARD_DEVIATION 6 • n=5 Participants
Sex: Female, Male
Female
2 Participants
n=5 Participants
2 Participants
n=7 Participants
4 Participants
n=5 Participants
Sex: Female, Male
Male
12 Participants
n=5 Participants
9 Participants
n=7 Participants
21 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants
n=5 Participants
6 Participants
n=7 Participants
12 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
8 Participants
n=5 Participants
5 Participants
n=7 Participants
13 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
White
13 Participants
n=5 Participants
11 Participants
n=7 Participants
24 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
14 participants
n=5 Participants
10 participants
n=7 Participants
24 participants
n=5 Participants
Region of Enrollment
South America
0 participants
n=5 Participants
1 participants
n=7 Participants
1 participants
n=5 Participants

PRIMARY outcome

Timeframe: The 6-MWD will be measured at 0 and 3 months.

Change in 6 Minute Walk Distance from Baseline to 3 Months

Outcome measures

Outcome measures
Measure
Arm 1
n=14 Participants
enroll in pulmonary rehabilitation program pulmonary rehabilitation: structured exercise program
Arm 2
n=11 Participants
no structured exercise
6 Minute Walk Distance
-6.2 meters
Standard Deviation 86.9
-15.3 meters
Standard Deviation 42.9

SECONDARY outcome

Timeframe: Markers of oxidant stress will be measured in all subjects before randomization after exercise testing at 0 months.

Plasma F2-isoprostanes measured in all subjects before and after exercise testing at baseline.

Outcome measures

Outcome measures
Measure
Arm 1
n=25 Participants
enroll in pulmonary rehabilitation program pulmonary rehabilitation: structured exercise program
Arm 2
n=25 Participants
no structured exercise
Systemic Markers of Oxidant Stress
16.48 pg/mL
Standard Deviation 10.10
17.96 pg/mL
Standard Deviation 10.05

SECONDARY outcome

Timeframe: Maximum O2 uptake will be measured at 0 and 3 months.

Change in 6 peak O2 uptake from Baseline to 3 Months

Outcome measures

Outcome measures
Measure
Arm 1
n=14 Participants
enroll in pulmonary rehabilitation program pulmonary rehabilitation: structured exercise program
Arm 2
n=11 Participants
no structured exercise
Maximum Oxygen Uptake
-35 mL/minute
Standard Error 71
-119 mL/minute
Standard Error 62

Adverse Events

Arm 1

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Arm 2

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Robert M Jackson, MD

MVAHS

Phone: 305-575-3548

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place